Emmanuel Mbualungu, MD
Internal Medicine · Washington, DCNPI 1881749166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 1,118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,896 and has fallen 56.5% since, to $1,695 in 2025. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,118 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- Amgen$2K
- Gilead$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Lilly USA, LLC$1K
- plus $11K from 38 others
Across 3 payments — averaging $29.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$88
What the payments were for
- Food & beverage$20,74898%
- Education$5322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,280 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $176,814 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $150,234 |
| EliquisApixaban | 104 | $142,667 |
| JardianceEmpagliflozin | 65 | $90,125 |
| FarxigaDapagliflozin Propanediol | 50 | $76,285 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $42,615 |
| KerendiaFinerenone | 41 | $41,451 |
| MounjaroTirzepatide | 34 | $41,074 |
| XareltoRivaroxaban | 26 | $40,614 |
| LinzessLinaclotide | 33 | $37,360 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $32,325 |
| EntrestoSacubitril/Valsartan | 18 | $26,404 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $17,832 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $16,604 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $15,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,386 | $176,814141 claims |
| GileadBiktarvy | $1,338 | $150,23437 claims |
| PfizerEliquis | $846 | $142,667104 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $550 | $107,95778 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $3,009 | $102,710103 claims |
| MerckJanumet, Janumet Xr | $840 | $48,24335 claims |
| GSKTrelegy Ellipta | $1,025 | $42,61539 claims |
| BayerKerendia | $691 | $41,45141 claims |
| Lilly USA, LLCMounjaro | $1,061 | $41,07434 claims |
| Johnson & JohnsonXarelto | $418 | $40,61426 claims |
| AbbVieLinzess, Synthroid | $912 | $39,89156 claims |
| NovartisEntresto | $824 | $26,40418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.